X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Procter & Gamble Health with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs AJANTA PHARMA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH AJANTA PHARMA PROCTER & GAMBLE HEALTH/
AJANTA PHARMA
 
P/E (TTM) x 59.8 20.5 291.3% View Chart
P/BV x 10.5 3.5 295.3% View Chart
Dividend Yield % 0.3 1.0 32.6%  

Financials

 PROCTER & GAMBLE HEALTH   AJANTA PHARMA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-17
AJANTA PHARMA
Mar-19
PROCTER & GAMBLE HEALTH/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,3581,422 95.5%   
Low Rs933898 103.9%   
Sales per share (Unadj.) Rs665.0233.5 284.8%  
Earnings per share (Unadj.) Rs56.644.0 128.7%  
Cash flow per share (Unadj.) Rs72.552.2 139.0%  
Dividends per share (Unadj.) Rs15.009.00 166.7%  
Dividend yield (eoy) %1.30.8 168.8%  
Book value per share (Unadj.) Rs441.7255.1 173.2%  
Shares outstanding (eoy) m16.6088.02 18.9%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x1.75.0 34.7%   
Avg P/E ratio x20.226.4 76.7%  
P/CF ratio (eoy) x15.822.2 71.1%  
Price / Book Value ratio x2.64.5 57.0%  
Dividend payout %26.520.5 129.5%   
Avg Mkt Cap Rs m19,011102,081 18.6%   
No. of employees `0001.56.8 22.7%   
Total wages/salary Rs m1,6964,307 39.4%   
Avg. sales/employee Rs Th7,150.03,022.6 236.6%   
Avg. wages/employee Rs Th1,098.7633.4 173.5%   
Avg. net profit/employee Rs Th608.2569.1 106.9%   
INCOME DATA
Net Sales Rs m11,04020,554 53.7%  
Other income Rs m240211 113.7%   
Total revenues Rs m11,27920,765 54.3%   
Gross profit Rs m1,3765,664 24.3%  
Depreciation Rs m264721 36.6%   
Interest Rs m012 0.0%   
Profit before tax Rs m1,3525,143 26.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1700-   
Tax Rs m5831,273 45.8%   
Profit after tax Rs m9393,870 24.3%  
Gross profit margin %12.527.6 45.2%  
Effective tax rate %43.124.8 174.2%   
Net profit margin %8.518.8 45.2%  
BALANCE SHEET DATA
Current assets Rs m7,52311,812 63.7%   
Current liabilities Rs m2,2533,776 59.6%   
Net working cap to sales %47.739.1 122.1%  
Current ratio x3.33.1 106.8%  
Inventory Days Days5277 67.4%  
Debtors Days Days4182 49.7%  
Net fixed assets Rs m1,24014,398 8.6%   
Share capital Rs m166175 94.6%   
"Free" reserves Rs m7,16722,277 32.2%   
Net worth Rs m7,33322,452 32.7%   
Long term debt Rs m07 0.0%   
Total assets Rs m9,91226,962 36.8%  
Interest coverage xNM444.3-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.10.8 146.1%   
Return on assets %9.514.4 65.8%  
Return on equity %12.817.2 74.3%  
Return on capital %20.823.0 90.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,01510,682 9.5%   
Fx outflow Rs m3,0432,102 144.8%   
Net fx Rs m-2,0288,580 -23.6%   
CASH FLOW
From Operations Rs m5373,748 14.3%  
From Investments Rs m-476-2,228 21.4%  
From Financial Activity Rs m-220-1,475 14.9%  
Net Cashflow Rs m-16045 -352.9%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 1.6 1,174.2%  
FIIs % 1.0 7.6 13.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 17.0 171.2%  
Shareholders   28,591 20,968 136.4%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  GSK PHARMA  PANACEA BIOTECH  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex below 38,000-Mark, HUL, L&T Q1FY20 Results, and Top Stocks in Action Today(Pre-Open)

On Tuesday, Indian share markets extended their decline for the 4th day as markets witnessed selling pressure during closing hours.

Related Views on News

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Driverless Cars are Here. And This Tiny Company is in the Lead...(The 5 Minute Wrapup)

Jul 17, 2019

This future-ready company thrives on the pace of technological change.

Here's Why This Smallcap Will Beat the Big Autos in the EV Race(Profit Hunter)

Jul 16, 2019

As the conventional auto sector faces existential crisis, my latest smallcap recommendation is all set to ride the electric vehicle disruption and rise in new age vehicles.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Jul 23, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS